EpigenDx

Founded in 1962, E. Benson Hood Laboratories is one of the first companies to introduce medical devices focused on managing specific medical conditions associated with head, neck and chest. Based in Pembroke, Mass., the company offers a array of products, such as adjustable reconstruction tube, angled stem t-tubes with or without rings, esophageal reconstruction tube, tracheal t-tubes with ultra-smooth plus, ultra-smooth plus surface treatment and many more. In addition, it offers a complete line of proximal and distal tracheal and bronchial silicone stents. E. Benson Hood Laboratories is certified to ISO 9001:2000 Quality management systems-Requirements and ISO 13485:2003 Quality systems-Medical Devices.

Giner Labs, established in 1973, is a leading research and development center located in Auburndale, MA, specializing in advanced electrochemical technologies. With over 50 years of expertise, the company focuses on creating innovative solutions in areas such as electrochemical sensors, electrolyzers, fuel cells, advanced materials, and medical devices. Their mission is to develop technologies that significantly impact various sectors, including clean energy, medical applications, and aerospace and defense. Giner Labs excels in translating groundbreaking research into tangible products, bridging the gap between scientific advancements and market implementation to drive progress and bring ideas to life. Generated from the website

AVI BioPharma is a biopharmaceutical company that develops drugs to treat life-threatening diseases using its patented third generation antisense technology. It has completed clinical trials with its NeuGene antisense drugs in more than 300 subjects, addressing cardiovascular restenosis, infectious diseases, cancer, polycystic kidney disease and drug metabolism. Its most advanced cardiovascular program is for restenosis, where it has completed Phase II trials, evaluating its drug, Resten-NG. AVI BioPharma is also in a Phase II clinical trial with a drug for Hepatitis C infection and its influenza A drug candidate has been confirmed to have efficacy against avian influenza H5N1 in preclinical studies. AVI BioPharma maintains a location in Portland, Ore.